Shares of CryoLife Inc. (NYSE:CRY) shot up 2% during trading on Friday . The stock traded as high as $15.65 and last traded at $15.63, with a volume of 97,005 shares trading hands. The stock had previously closed at $15.33.

Several research firms have recently commented on CRY. Canaccord Genuity reissued a “buy” rating on shares of CryoLife in a report on Tuesday, July 26th. Zacks Investment Research raised CryoLife from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Tuesday, July 12th. Lake Street Capital began coverage on CryoLife in a report on Wednesday, June 15th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $16.00 price target on shares of CryoLife in a report on Wednesday, July 27th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. CryoLife has an average rating of “Buy” and a consensus target price of $15.00.

The stock has a 50-day moving average of $13.99 and a 200 day moving average of $12.03. The stock has a market capitalization of $534.50 million and a PE ratio of 50.22.

CryoLife (NYSE:CRY) last posted its earnings results on Monday, July 25th. The company reported $0.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.11. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $35.50 million. During the same period last year, the company posted $0.03 earnings per share. The firm’s revenue for the quarter was up 32.6% compared to the same quarter last year. Equities analysts predict that CryoLife Inc. will post $0.24 EPS for the current year.

In other news, Director Ronald D. Mccall sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the completion of the transaction, the director now directly owns 156,248 shares of the company’s stock, valued at $1,806,226.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director C Elkins Ronald sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $14.00, for a total value of $28,000.00. Following the transaction, the director now directly owns 103,586 shares of the company’s stock, valued at $1,450,204. The disclosure for this sale can be found here.

An institutional investor recently raised its position in CryoLife stock. Morgan Stanley increased its stake in shares of CryoLife Inc. (NYSE:CRY) by 1.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,605,563 shares of the company’s stock after buying an additional 21,067 shares during the period. Morgan Stanley owned approximately 5.64% of CryoLife worth $17,308,000 at the end of the most recent reporting period.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.